faricimab

Home
Ligands
faricimab

GtoPdb Ligand ID: 11420

Synonyms: faricimab-svoa | RG-7716 | RG7716 | RO-6867461 | RO6867461 | Vabysmo®

faricimab is an approved drug (EMA & FDA (2022))

Comment: Faricimab is a bispecific monoclonal antibody that simultaneously binds to angiopoietin 2 (Ang2) and vascular endothelial growth factor A (VEGF-A) [3-4]. It is an angiogenesis inhibitor. The FcRn and FcγR binding sites of faricimab have been modified to disable its Fc‐mediated effector functions. Faricimab does not bind to Ang1 [4].

No information available.

No information available.

Summary of Clinical Use
Faricimab was evaluated for efficacy in eye diseases that involve aberrant vascularisation, including diabetic macular edema (DME), wet age-related macular degeneration (wAMD) and branch retinal vein occlusion (BRVO). Phase 2 studies demonstrated clinical efficacy for the treatment of wAMD, and superiority to the anti-VEGF-A biologic ranibizumab in the management of DME [1]. Faricimab (Vabysmo®) was FDA approved in January 2022, as a treatment for both wAMD and DME.

Summary of Clinical Use

Faricimab was evaluated for efficacy in eye diseases that involve aberrant vascularisation, including diabetic macular edema (DME), wet age-related macular degeneration (wAMD) and branch retinal vein occlusion (BRVO). Phase 2 studies demonstrated clinical efficacy for the treatment of wAMD, and superiority to the anti-VEGF-A biologic ranibizumab in the management of DME [1]. Faricimab (Vabysmo®) was FDA approved in January 2022, as a treatment for both wAMD and DME.

Clinical Trials
Clinical Trial ID	Title	Type	Source	Comment	References
NCT03823287	A Study to Evaluate the Efficacy and Safety of Faricimab in Participants With Neovascular Age-Related Macular Degeneration (TENAYA)	Phase 3 Interventional	Hoffmann-La Roche
NCT04740905	A Study to Evaluate the Efficacy and Safety of Faricimab in Participants With Macular Edema Secondary to Branch Retinal Vein Occlusion	Phase 3 Interventional	Hoffmann-La Roche
NCT03622580	A Study to Evaluate the Efficacy and Safety of Faricimab (RO6867461) in Participants With Diabetic Macular Edema (YOSEMITE)	Phase 3 Interventional	Hoffmann-La Roche
NCT04432831	A Study to Evaluate the Long-Term Safety and Tolerability of Faricimab in Participants With Diabetic Macular Edema	Phase 3 Interventional	Hoffmann-La Roche
NCT03038880	Study to Evaluate Faricimab (RO6867461; RG7716) for Extended Durability in the Treatment of Neovascular Age Related Macular Degeneration	Phase 2 Interventional	Hoffmann-La Roche		2
NCT02699450	A Study of Faricimab (RO6867461) in Participants With Center-Involving Diabetic Macular Edema	Phase 2 Interventional	Hoffmann-La Roche		1,5